🔗 Share this article

The Nobel Prize in Physiology or Medicine was granted for transformative discoveries that clarify how the body's defense network attacks harmful pathogens while sparing the body's own cells.

A trio of esteemed researchers—from Japan Shimon Sakaguchi and American experts Mary Brunkow and Fred Ramsdell—received this accolade.

The research identified specialized "sentinels" within the defense system that eliminate malfunctioning defense cells that could harming the organism.

The findings are now enabling new therapies for immune disorders and cancer.

These laureates will share a prize fund valued at 11 million SEK.

Crucial Findings

"Their research has been essential for comprehending how the body's defenses functions and the reason we do not all suffer from severe self-attack conditions," stated the chair of the award panel.

The trio's research explain a fundamental question: How does the immune system defend us from numerous invaders while keeping our healthy cells unharmed?

Our body's protection system employs immune cells that search for indicators of disease, even pathogens and bacteria it has never encountered.

These defenders employ detectors—called recognition units—that are generated by chance in a vast number of combinations.

That gives the defense network the capacity to fight a wide array of threats, but the unpredictability of the process unavoidably creates immune cells that may target the host.

Protectors of the Body

Researchers previously knew that some of these problematic white blood cells were eliminated in the immune organ—the site where white blood cells develop.

This year's Nobel Prize honors the discovery of regulatory T-cells—known as the immune system's "peacekeepers"—which patrol the body to neutralize other defenders that assault the healthy cells.

We know that this process malfunctions in self-attack conditions such as juvenile diabetes, multiple sclerosis, and RA.

The prize committee added, "The findings have laid the foundation for a novel area of research and spurred the development of new treatments, for example for cancer and autoimmune diseases."

Regarding cancer, regulatory T-cells block the system from attacking the tumor, so studies are focused on lowering their quantity.

For autoimmune diseases, trials are testing boosting T-reg cells so the organism is not being harmed. A comparable approach could also be effective in minimizing the risks of transplanted organ rejection.

Innovative Experiments

Prof Shimon Sakaguchi, from Osaka University, conducted experiments on rodents that had their thymus extracted, causing self-attack conditions.

The researcher showed that injecting immune cells from healthy animals could stop the illness—implying there was a system for blocking immune cells from harming the host.

Mary Brunkow, affiliated with the Institute for Systems Biology in a US city, and Dr. Ramsdell, now at Sonoma Biotherapeutics in San Francisco, were studying an genetic autoimmune disease in mice and people that led to the identification of a genetic factor critical for the way regulatory T-cells function.

"Their groundbreaking work has revealed how the body's defenses is controlled by T-reg cells, stopping it from accidentally attacking the healthy cells," said a prominent biological science expert.

"This research is a striking illustration of how basic physiological study can have broad implications for public health."